Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Presse Med ; 36(11 Pt 1): 1527-35, 2007 Nov.
Artigo em Francês | MEDLINE | ID: mdl-17662570

RESUMO

OBJECTIVE: To assess the efficacy of percutaneous laser disc decompression for patients with radicular pain due to lumbar disc hernia and to identify factors that may predict outcome. METHODS: The study included all patients treated with percutaneous laser disc decompression from May 2003 through May 2005 at Reims University Hospital and the Courlancy Clinic of Reims. Each patient had previous undergone at least six weeks of conventional medical treatment. The same technique, with either a laser diode or Nd: YAG, was used under endoscopic control and with neuroleptanalgesia. They were seen at 1, 3, 6 and 12 months. The principal evaluation criteria were the course of radicular pain, return to work, and need for surgery. RESULTS: We reexamined 149 patients 1 month after the procedure, 135 after 3 months, 102 after 6 months and 59 a year after the procedure. At a month after surgery, radicular pain had decreased by at least half, and sometimes even completely disappeared in 63.1% of patients at 1 month, 66.6% at 3 months, 73.5% at 6 months, and 83.1% at 12 months, while 24%, 50,4%, 61.2%, and 67.3%, respectively, had returned to work. No patient had serious complications. Finally, 45 of the 149 (30.2%) patients chose to have a traditional surgical procedure after percutaneous laser disc decompression. CONCLUSION: Percutaneous laser disc decompression is effective, noninvasive and well tolerated for patients with radicular pain due to lumbar disc hernia.


Assuntos
Descompressão Cirúrgica/métodos , Deslocamento do Disco Intervertebral/complicações , Terapia a Laser , Dor Lombar/cirurgia , Adulto , Feminino , Humanos , Dor Lombar/etiologia , Masculino , Estudos Prospectivos
3.
Joint Bone Spine ; 72(6): 544-9, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16226477

RESUMO

OBJECTIVE: The objective of this study was to identify prognostic factors in a uniform population of older patients with myeloma. METHODS: Thirty-one study centers in France included 148 patients who were older than 55 years at diagnosis and were followed up until death or for at least 10 years. The following tests were available for all patients: blood cell counts; serum, and urinary protein electrophoresis; and serum levels of creatinine, calcium, beta2 microglobulin (beta2m), lactic dehydrogenase (LDH), and C-reactive protein (CRP). RESULTS: Mean age was 71.9 years, median survival was 34 months, and mean survival was 47 months. In the univariate analysis, factors significantly associated with higher mortality were male gender (odds ratio [OR], 1-2.12), age older than 70 years (OR, 1.10-2.28), serum albumin<30 g/l (OR, 1.16-3.28), serum creatinine>100 micromol/l (OR, 1.34-2.81), beta2m>6 mg/l (OR, 1.78-4), CRP>6 mg/l (OR, 1.44-3.06), hemoglobin<10 g/dl (OR, 1.8-2.23). In the multivariate analysis, only two factors significantly predicted a higher risk of death: beta2m>6 mg/l (OR=2.439 [1.59-3.76]) and CRP>6 mg/l (OR=1.76 [1.18-2.63). beta2m level was >6 mg/l in 41 (27.7%) patients and CRP was >6 mg/l in 61 (43.6%) patients. Other potential prognostic factors such as chromosome 13 deletion were not investigated because they were not available for all study patients. CONCLUSIONS: The strength of this study is the 10-year follow-up in a uniform patient cohort. beta2m and CRP independently predicted the risk of death.


Assuntos
Mieloma Múltiplo/mortalidade , Idoso , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Proteína C-Reativa/análise , Creatinina/sangue , Feminino , Humanos , Masculino , Melfalan/administração & dosagem , Pessoa de Meia-Idade , Mieloma Múltiplo/sangue , Mieloma Múltiplo/tratamento farmacológico , Prednisolona/administração & dosagem , Prognóstico , Fatores de Risco , Microglobulina beta-2/sangue
4.
Joint Bone Spine ; 72(3): 260-2, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15850999

RESUMO

Tonic dystonia is an underrecognized complication of reflex sympathetic dystrophy syndrome (RSDS) characterized by an increase in muscle tone at the site of injury. Case-reports.- We describe five cases of tonic dystonia complicating RSDS of the lower extremity. There were four women and one man, with a mean age of 52 years. In addition to the typical features of RSDS, the patients had fixed equinovarus of the foot with hyperextension or hyperflexion of the great toe. In two patients, examination after spinal anesthesia showed that the deformity was reducible. Spontaneous resolution of the dystonia occurred in one patient. Another patient failed to experience meaningful improvement after a motor block followed by botulinic toxin injections. In two patients, the same treatment was followed by a slight improvement. Treatment options are still being evaluated in the last patient. Discussion.- Tonic dystonia is an underrecognized complication of RSDS that often develops after a minor injury yet causes prolonged pain and disability. Spread of the dystonia to other sites is not infrequent. The underlying mechanisms remain unclear but may involve dysfunction of the central or peripheral nervous system or psychogenic factors. Suggested treatments include motor block, intrathecal baclofen, sympathetic block, and sympathectomy. However, none of these treatments has been proved effective. Conclusion.- The five cases described here provide useful information on RSDS-associated tonic dystonia, a condition that runs a protracted course and remains difficult to manage.


Assuntos
Distonia/fisiopatologia , Doenças do Pé/fisiopatologia , , Distrofia Simpática Reflexa/fisiopatologia , Adulto , Idoso , Distonia/etiologia , Distonia/terapia , Pé Equino/etiologia , Pé Equino/fisiopatologia , Pé Equino/terapia , Feminino , Doenças do Pé/etiologia , Doenças do Pé/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Distrofia Simpática Reflexa/complicações , Distrofia Simpática Reflexa/terapia , Falha de Tratamento
5.
J Toxicol Environ Health A ; 65(8): 603-15, 2002 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-11991633

RESUMO

Since gallium is a metal ion used in semiconductor industry, the toxicological effects were previously evaluated in mammals but the ecotoxicological impacts remain unknown. In term of ecotoxicological risk assessment, the median lethal concentration (LC50 for 96 h of gallium to carp (Cyprinus carpio L.) and the oxidative response of carp phagocytes after the fish were exposed to sublethal levels of gallium were determined. The LC50 of gallium on C. carpio at 96 h was estimated as 96.25 +/- 14.3 mg/L. To determine the effect in vivo of gallium on the phagocyte response, fish were exposed for 96 h to 5 or 50 mg Ga(3+)/L. Carp maintained for 48 or 96 h in water containing 50 mg/L gallium had a significant fall in phagocyte oxidative burst activity in comparison with controls, as well as decreased leukocyte number in blood and increased cytotoxicity. To determine the effect in vitro of gallium on the phagocyte response, isolated phagocytes were exposed for 5 or 15 min to 50 nM, 500 nM, or 5, 50, 100, or 200 microM of Ga(3+). The oxidative burst was increased after in vitro incubation of phagocytes with 50 or 500 nM gallium for 15 min or with 500 nM gallium for 5 min. Moreover, for 50, 100, or 200 microM gallium, the oxidative burst activity of carp phagocytes was significantly decreased. Results indicate that the lethal toxicity of gallium for carp of gallium is not as high as for other metal ions. However, gallium was immunosuppressive for carp at the highest concentrations used (from 50 microM) in vivo and in vitro. At low concentrations, it could be an immunostimulant as observed in vitro.


Assuntos
Carpas/imunologia , Gálio/toxicidade , Fagócitos/efeitos dos fármacos , Explosão Respiratória/efeitos dos fármacos , Animais , Células Cultivadas , Imunossupressores/toxicidade , Dose Letal Mediana , Fagócitos/imunologia , Espécies Reativas de Oxigênio/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...